Gaucher disease is a massively clinically heterogeneous recessive gene dominance disorder. Chronic fatigue, hepatomegaly, anemia or thrombocytopenia, painless splenomegaly, pathologic fractures, anemia, or thrombocytopenia. Additionally, the disease makes it easier to bruise and experience nosebleeds. The Gaucher Disease Treatment Market, which manifests in three subtypes, is brought on by a lack of the glucocerebrosidase enzyme.
In the past, most patients received the recombinant enzyme imiglucerase. The disease's visceral and hematologic symptoms were successfully reversed by the therapy. The skeletal disease's slow responses and pulmonary involvement, however, are relatively resistant to the enzyme.
Read More @ https://cmiinfonest.blogspot.com/2022/08/global-gaucher-disease-treatment-market.html
